No Detail Found!

Evaluating the Utility of Beta Blockers in Arteriovenous Malformations and Related Vascular Lesions: A Systematic Review

Author(s)
Hassan Ahmed Alzahrani Department of Vascular and Endovascular Surgery, Alnoor Specialist Hospital, Mecca, Saudi Arabia; Neurosciences Center, Royal Medical Services, Bahrain; Department of Neurosurgery, Weill Cornell University, Houston Methodist, New York, United State
Hosam Maher Al-Jehani2 The Neurovascular Disease Center, Imam Abdulrahman Alfaisal University, Saudi Arabia
Mohammed Maher Aljehani Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, McGill University, Canada
Faisal Saud Alsulaimani Neurosciences Center, Royal Medical Services, Bahrain
Mohammed Mousa Quaider Department of Neurosurgery, Weill Cornell University, Houston Methodist, New York, United State
Manaf Mohammed Alsaqaf Department of Neurosurgery, Weill Cornell University, Houston Methodist, New York, United State
Abdullah Ali A. Alshamrani Department of Neurosurgery, Weill Cornell University, Houston Methodist, New York, United State
Abstract
Objectives: To synthesize the available clinical evidence on beta-blocker therapy for arteriovenous malformations (AVMs) and related vascular lesions and to clarify the distinction between evidence derived from true AVMs and evidence derived from infantile haemangioma (IH)-dominant cohorts. Methods: This systematic review was prepared in accordance with PRISMA. PubMed, Scopus and Web of Science were searched for studies published between January 2016 and October 2025, supplemented by bibliography screening and Google Scholar searching. Eligible studies included randomized trials, observational studies and case reports evaluating systemic or topical beta-blockers. Because the included literature was clinically heterogeneous, a narrative synthesis was performed. Primary outcomes were radiological or clinical lesion response and symptom improvement; secondary outcomes were adverse events, need for additional intervention, recurrence/progression and functional outcomes. Results: Eighteen studies were included (2 randomized controlled trials, 10 observational studies and 6 case reports). The evidence base was dominated by IH and related vascular lesions, whereas true AVM-specific evidence was limited to case reports and small retrospective series. Across AVM-focused reports, propranolol was generally used at 1-2 mg/kg/day or equivalent fixed doses, usually for several months and was associated more often with symptom improvement or lesion stabilisation than with consistent radiological shrinkage. The randomized trials addressed IH rather than true AVMs and both were judged to have high risk of bias. Adverse effects included bradycardia, hypotension, wheeze, hypoglycaemia and gastrointestinal intolerance. Conclusion: Current evidence strongly supports beta-blockers in IH, but does not establish them as definitive primary therapy for true AVMs. In selected AVM cases, beta-blockers may provide symptomatic benefit or short-term stabilisation; however, they should presently be regarded as adjunctive or exploratory treatment pending higher-quality AVM-specific studies.
Publication Details
Page(s) 17-25
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: s1, Year: 2026

Request the full text from PASTIC

Keywords
Arteriovenous Malformations, Systematic review, Vascular anomalies, Infantile Haemangioma, Timolol, Propranolol
References
.2021 .Management of symptomatic adult penile urethral arteriovenous malformation. ” Urology Case Reports, 101738 : 101738.
Uller W. .2014 .Arteriovenous malformations. ” Seminars in Pediatric Surgery, 07(2014) : 203-207.
Krol A,C.J. MacArthur. A . .Congenital hemangiomas: rapidly involuting and noninvoluting congenital hemangiomas. ” Archives of Facial Plastic Surgery, 7(2005) : 307-311.
Gibson C.R.,Barnacle A.M. . .Vascular anomalies: special considerations in children. ” CVIR Endovascular, 3(2020) : 60.
Lee A.,Patel N.A. .2021 .Systematic review of pediatric mandibular arteriovenous malformations. International Journal of Pediatric Otorhinolaryngology, 110942 : 110942.
Fourn Le .2014 .Efficacy and safety of embolization in arteriovenous malformations of the extremities and head and neck: a retrospective study of 32 cases. European Journal of Dermatology, 2450(2015) : 52-56.
Gabeff R. .2019 .Efficacy and tolerance of sirolimus (rapamycin) for extracranial arteriovenous malformations in children and adults. ” Acta Dermato-Venereologica, 99(12) : 00015555-3273.
Sethuraman G. . .Management of infantile hemangiomas: current trends. ” Journal of Cutaneous and Aesthetic Surgery, 7(2014) : 0974-2077.
Goss J.A. . .Propranolol treatment of vascular anomalies other than infantile hemangioma. ” Journal of Craniofacial Surgery, 28(2017) : 2001-2003.
Lu J. .2017 .Propranolol as a potentially novel treatment of arteriovenous malformations. ” JAAD Case Reports, 11(2018) : 355-358.
Pföhler C. .2013 .Successful treatment of a congenital extratruncal vascular malformation by orally administered propranolol. ” Journal of Dermatological Treatment, 869301(2015) : 59-62.
Kum J.J.,Khan Z.A. .2014 .Mechanisms of propranolol action in infantile hemangioma. ” Dermato-Endocrinology, 979699(2015) : e979699.
Padhiyar J.K. .2018 .Efficacy and safety of propranolol on the proliferative phase of infantile hemangioma: a hospital-based prospective study. Indian Journal of Paediatric Dermatology, 75 : 17-229.
Léauté-Labrèze C. .2008 .Propranolol for severe hemangiomas of infancy. ” New England Journal of Medicine, 358(24) : 2649-2651.
Mohanty P.K. . .A randomised controlled study on efficacy of propranolol, prednisolone and propranolol with prednisolone in infantile hemangioma. ” Journal of the Pediatrics Association, 7(2018) : 166.
Lee J.C. . .Propranolol therapy in infantile hemangioma: it is not just about the beta. ” Plastic and Reconstructive Surgery, 147(2021) : 875-885.
Rotter A.,Z.N.P. A. .2017 .Infantile hemangioma: pathogenesis and mechanisms of action of propranolol. ” Journal der Deutschen Dermatologischen Gesellschaft, 15(12) : 1185-1190.
Gupta R. . .Propranolol for vascular anomalies: efficacy and complications in pediatric patients. ” Journal of Indian Association of Pediatric Surgeons, 117(2023) : 22-205.
Page M.J. .2021 .The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. ” BMJ, 372 : n71.
Moola S. .2017 .Chapter 7: systematic reviews of etiology and risk.” JBI Manual for Evidence Synthesis. , : .
Higgins J.P.T.,Cochrane J.P.T. .2021 .Chapter 8: assessing risk of bias in a randomized trial. ” Cochrane Handbook for Systematic Reviews of Interventions, version 6, : .
Ong-A-Liem G.S. .2022 .Use of beta-blocker in cerebral proliferative angiopathy: a case report. ” Interdisciplinary Neurosurgery: Advanced Techniques and Case Management, 101663 : 101663.
Panda S.K. . .Propranolol in congenital hepatic arteriovenous malformation. Indian Journal of Pediatrics, 90(2023) : 952.
Chastanet S. .2022 .Effect of beta-blockers on extracranial arteriovenous malformations. ” Acta Dermato-Venereologica, 102 : 1412.
Ba H. .2020 .Beta blocker therapy for congenital hepatic arteriovenous fistula in two neonates. , 00163(2020) : 163.
J.W.C.H. . .Randomised controlled trial: can topical timolol maleate prevent complications for small superficial infantile haemangiomata in high-risk areas?” Pediatric Research. , 88(2020) : 756-760.
Diociaiuti A. .2020 .Cutaneous infantile haemangiomas with intracranial and intraspinal involvement: a European multicentre experience and review. ” Acta DermatoVenereologica, 100(16) : 00015555-3608.
Singh G. . .Oral propranolol in the treatment of ulcerated bleeding scrotal arteriovenous malformation. ” Journal of Indian Association of Pediatric Surgeons, 232(2020) : 19-403.
Tani S. .2020 .Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. ” Drug Discoveries and Therapeutics, 03014(2020) : 89-92.
Xu P. .2019 .Lip infantile hemangiomas involving the vermillion border have worse outcomes and prognosis to oral propranolol than lesions confined to one side of the vermillion. ” Journal of Oral and Maxillofacial Surgery, 09(2020) : 446-454.
Igarashi A. .2018 .A case of an infant with extremely low birth weight and hypothyroidism associated with massive cutaneous infantile hemangioma. ” Journal of Pediatric Endocrinology and Metabolism, 31(12) : 1377-1380.
Wu H.W. .2018 .Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. ” Frontiers in Oncology, 00605(2018) : 605.
Xu M.N. . .Individualized treatment for infantile hemangioma. ” Journal of Craniofacial Surgery, 29(2018) : 1876-1879.
Kim K.H. .2017 .Comparison of efficacy and safety between propranolol and steroid for infantile hemangioma: a randomized clinical trial. ” JAMA Dermatology, 0250(2017) : 529-536.
Wang Y. . .Efficacy and safety of 2% topical propranolol cream for the treatment of proliferating infantile strawberry hemangiomas. Indian Journal of Pediatrics, 84(2017) : 425-429.
Yu X. . .LUMBAR syndrome: a case manifesting as cutaneous infantile hemangiomas of the lower extremity, perineum and gluteal region and a review of published work. ” Journal of Dermatology, 44(2017) : 13763-8138.
Macca L. .2022 .Update on treatment of infantile hemangiomas: what's new in the last five years?” Frontiers in Pharmacology. , 879602 : 879602.
Demirci O.,Celayir A. .2020 .Prenatal diagnosis and treatment of intrahepatic arteriovenous fistulas: case reports and the literature review. ” Journal of Maternal-Fetal and Neonatal Medicine, 1731466(2022) : 837-845.
Simsek E.,N Y Y Y Y Y Y Y E.,a N Y Y Y Y Y Y Y E.,N Y Y Y Y Y Y Y E. . .0 s s s s s s s a 02 o e. -0055, 31(2018) : 823-827.
0

Citations

0

Downloads

16

Views